Patents by Inventor Minna D. Balbas

Minna D. Balbas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of resistant androgen receptor
    Patent number: 11739069
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: August 29, 2023
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • MODULATORS OF RESISTANT ANDROGEN RECEPTOR
    Publication number: 20200172504
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Application
    Filed: October 21, 2019
    Publication date: June 4, 2020
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • Modulators of resistant androgen receptor
    Patent number: 10450294
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 22, 2019
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • Androgen receptor variants and methods for making and using
    Patent number: 10206911
    Abstract: The present invention encompasses the recognition that an F876L mutation of the androgen receptor (AR) gene confers resistance to the antiandrogens enzalutamide (MDV3100) and ARN-509 and is associated with incidence and/or risk of castration resistant prostate cancer (CRPC). The present invention also provides other AR polypeptide sequences associated with increased incidence and/or risk of CRPC. The present invention also provides screening methods for identification and/or characterization of novel AR polypeptide sequences associated with increased incidence and/or risk of CRPC via exposure to antiandrogens and for identification and/or characterization of agents to treat and/or reduce risk of CRPC by virtue of their effect on AR transcriptional activation.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: February 19, 2019
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Charles L. Sawyers, Philip Watson
  • MODULATORS OF RESISTANT ANDROGEN RECEPTOR
    Publication number: 20170320849
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Application
    Filed: May 12, 2017
    Publication date: November 9, 2017
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • Modulators of resistant androgen receptor
    Patent number: 9650359
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: May 16, 2017
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • MODULATORS OF RESISTANT ANDROGEN RECEPTOR
    Publication number: 20160257666
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Application
    Filed: May 18, 2016
    Publication date: September 8, 2016
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • Modulators of resistant androgen receptor
    Patent number: 9365542
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful in medicine, and particularly for treating any of a variety of diseases, disorders or conditions.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: June 14, 2016
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • MODULATORS OF RESISTANT ANDROGEN RECEPTOR
    Publication number: 20150274693
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful in medicine, and particularly for treating any of a variety of diseases, disorders or conditions.
    Type: Application
    Filed: October 25, 2013
    Publication date: October 1, 2015
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • ANDROGEN RECEPTOR VARIANTS AND METHODS FOR MAKING AND USING
    Publication number: 20150265587
    Abstract: The present invention encompasses the recognition that an F876L mutation of the androgen receptor (AR) gene confers resistance to the antiandrogens enzalutamide (MDV3100) and ARN-509 and is associated with incidence and/or risk of castration resistant prostate cancer (CRPC). The present invention also provides other AR polypeptide sequences associated with increased incidence and/or risk of CRPC. The present invention also provides screening methods for identification and/or characterization of novel AR polypeptide sequences associated with increased incidence and/or risk of CRPC via exposure to antiandrogens and for identification and/or characterization of agents to treat and/or reduce risk of CRPC by virtue of their effect on AR transcriptional activation.
    Type: Application
    Filed: October 25, 2013
    Publication date: September 24, 2015
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Minna D. Balbas, Charles L. Sawyers, Philip Watson